PHILADELPHIA, PA — Fore Biotherapeutics will present its corporate strategy at the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 15, putting its lead cancer drug plixorafenib before investors as the company advances the targeted therapy.
Fore is scheduled to deliver a corporate presentation at 7:45 a.m. ET. Management will also hold one-on-one meetings during the conference.
The company is developing plixorafenib, also known as FORE8394 or PLX8394, as its lead oncology asset. The drug is a V600 and non-V600 BRAF inhibitor designed to address treatment gaps associated with first- and second-generation BRAF inhibitors.
Fore describes itself as a registration-stage targeted oncology company focused on treatments for difficult-to-treat cancers.
Investors interested in arranging one-on-one meetings with Fore management can contact Argot Partners.
